Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02689882 · ClinicalTrials.gov registry record · Phase 1
"Pharmacokinetic Study of Nicotinamide Riboside"
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02689882 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 8 participants.
The verdict
NCT02689882, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Nicotinamide riboside (NR) has been available over the counter as a nutraceutical (Niagen®, ChromaDex, Inc.) since the summer of 2013. However, classical pharmacokinetic (PK) data for NR have not been reported in humans. This study will use a recently-developed, whole blood assay for NR to assess the pharmacokinetics of NR at a maximum dose of 1000 mg twice daily, and will collect history, physical examination and laboratory data to determine the safety and tolerability of NR in eight, healthy volunteers. In addition, whole blood nicotinamide adenine dinucleotide (NAD) levels will be measured at each time point, to determine whether this NR dose significantly raises whole blood NAD levels.
Interventions
- DIETARY_SUPPLEMENT nicotinamide riboside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02689882
The ClinicalTrials.gov registry entry for NCT02689882 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nicotinamide riboside is the first listed.
NCT02689882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02689882 about?
NCT02689882 is a clinical study titled ""Pharmacokinetic Study of Nicotinamide Riboside"". Nicotinamide riboside (NR) has been available over the counter as a nutraceutical (Niagen®, ChromaDex, Inc.) since the summer of 2013. However, classical pharmacokinetic (PK) data for NR have not been reported in humans. This study will use a recently-developed, whole blood assay for NR to assess th...
What is the current status of trial NCT02689882?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-11. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02689882?
The interventions under investigation include: nicotinamide riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02689882?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.